Epigenetic mechanisms of importance for drug treatment

Trends in Pharmacological Sciences

Volumn 35, Issue 8, 2014, Pages 384-396

  Ivanov, Maxim ^a   Barragan, Isabel ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 hydroxymethylcytosine; DNA methylation; epidrugs; epigenetic editing; histone modifications; pharmacoepigenetics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; AZACITIDINE; BUTYRIC ACID; CARBOPLATIN; DIETHYLSTILBESTROL; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; EXEMESTANE; GLUTATHIONE TRANSFERASE P1; HISTONE; HYDRALAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOCETINOSTAT; OPIATE; PANOBINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; RNA; ROMIDEPSIN; SECRETED FRIZZLED RELATED PROTEIN 5; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG; VALPROATE MAGNESIUM; VALPROIC ACID; VORINOSTAT;

ABCB1 GENE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DRUG ABUSE; DRUG METABOLISM; DRUG RESPONSE; ENZYME INHIBITION; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC VARIABILITY; GLIOMA; GPX3 GENE; GSTP1 GNEE; HEREDITY; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MGMT GENE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; OSCP1 GENE; OVARY CANCER; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PITX2 GENE; PLK2 GENE; PREDICTION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASSF1A GENE; REVIEW; RNA EDITING; SFRP5 GENE; SHIGELLOSIS; TFAP2E GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VAGINA TUMOR;

5-HYDROXYMETHYLCYTOSINE; DNA METHYLATION; EPIDRUGS; EPIGENETIC EDITING; HISTONE MODIFICATIONS; PHARMACOEPIGENETICS;

ANIMALS; DRUG THERAPY; EPIGENESIS, GENETIC; HUMANS; PHARMACOGENETICS;

EID: 84905513547     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.05.004     Document Type: Review

References (93)

1. S.C. Sim, and M. Ingelman-Sundberg Pharmacogenomic biomarkers: new tools in current and future drug therapy Trends Pharmacol. Sci. 32 2011 72 81
2. A.R. Shuldiner et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation Clin. Pharmacol. Ther. 94 2013 207 210
3. S.C. Su et al. Digging up the human genome: current progress in deciphering adverse drug reactions Biomed. Res. Int. 2014 2014 824343
4. A. How Kit et al. DNA methylation based biomarkers: practical considerations and applications Biochimie 94 2012 2314 2337
5. C.H. Arrowsmith et al. Epigenetic protein families: a new frontier for drug discovery Nat Rev. Drug Discov. 11 2012 384 400
6. W.D. Chen et al. Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver Hepatology 56 2012 1499 1509
7. J.P. Thomson et al. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver Nucleic Acids Res. 41 2013 5639 5654
8. R. Chatterjee, and C. Vinson CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression Biochim. Biophys. Acta 1819 2012 763 770
9. R.A. Irizarry et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores Nat. Genet. 41 2009 178 186
10. L. Burger et al. Identification of active regulatory regions from DNA methylation data Nucleic Acids Res. 41 2013 e155
11. V.M. Marx et al. Stereoselective access to Z and E macrocycles by ruthenium-catalyzed Z-selective ring-closing metathesis and ethenolysis J. Am. Chem. Soc. 135 2013 94 97
12. M.B. Stadler et al. DNA-binding factors shape the mouse methylome at distal regulatory regions Nature 480 2011 490 495
13. N. Sasai, and P.A. Defossez Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes Int. J. Dev. Biol. 53 2009 323 334
14. E.W. Tobi et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific Hum. Mol. Genet. 18 2009 4046 4053
15. L. Shen, and Y. Zhang 5-Hydroxymethylcytosine: generation, fate, and genomic distribution Curr. Opin. Cell Biol. 25 2013 289 296
16. M. Mellen et al. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system Cell 151 2012 1417 1430
17. R.M. Kohli, and Y. Zhang TET enzymes, TDG and the dynamics of DNA demethylation Nature 502 2013 472 479
18. G.P. Pfeifer et al. 5-Hydroxymethylcytosine and its potential roles in development and cancer Epigenet Chromatin 6 2013 10
19. M.A. Hahn et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis Cell Rep. 3 2013 291 300
20. M. Ivanov et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function Genome Biol. 14 2013 R83
21. M. Yu et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome Cell 149 2012 1368 1380
22. M.J. Booth et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution Science 336 2012 934 937
23. A.J. Bannister, and T. Kouzarides Regulation of chromatin by histone modifications Cell Res. 21 2011 381 395
24. K.H. Hansen, and K. Helin Epigenetic inheritance through self-recruitment of the polycomb repressive complex 2 Epigenetics 4 2009 133 138
25. J.S. Butler et al. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease Epigenomics 4 2012 163 177
26. M.G. Rosenfeld et al. Sensors and signals: a coactivator/corepressor/ epigenetic code for integrating signal-dependent programs of transcriptional response Genes Dev. 20 2006 1405 1428
27. X.Q. Wang et al. Shaping the Genome with Non-Coding RNAs Curr. Genomics 12 2011 307 321
28. R.A. Gupta et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis Nature 464 2010 1071 1076
29. X. Liu et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer J. Exp. Clin. Cancer Res. 32 2013 96
30. M. Kacevska et al. Perspectives on epigenetics and its relevance to adverse drug reactions Clin. Pharmacol. Ther. 89 2011 902 907
31. M. Kacevska et al. Epigenetic-dependent regulation of drug transport and metabolism: an update Pharmacogenomics 13 2012 1373 1385
32. M. Ivanov et al. Epigenomics and interindividual differences in drug response Clin. Pharmacol. Ther. 92 2012 727 736
33. S. Choudhuri et al. Molecular targets of epigenetic regulation and effectors of environmental influences Toxicol. Appl. Pharmacol. 245 2010 378 393
34. Y. Wu et al. Histone deacetylase 1 is required for carbamazepine-induced CYP3A4 expression J. Pharm. Biomed. Anal. 58 2012 78 82
35. M. Kacevska et al. DNA methylation dynamics in the hepatic CYP3A4 gene promoter Biochimie 94 2012 2338 2344
36. H. Heyn, and M. Esteller DNA methylation profiling in the clinic: applications and challenges Nat. Rev. Genet. 13 2012 679 692
37. N. Thon et al. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status Onco Targets Ther. 6 2013 1363 1372
38. J. Zhu et al. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer J. Exp. Clin. Cancer Res. 31 2012 80
39. D.M. Janzen et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy Cancer Res. 73 2013 4697 4710
40. A.P. Feinberg et al. The epigenetic progenitor origin of human cancer Nat. Rev. Genet. 7 2006 21 33
41. S. Kalari, and G.P. Pfeifer Identification of driver and passenger DNA methylation in cancer by epigenomic analysis Adv. Genet. 70 2010 277 308
42. S.D. Furdas et al. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates Arch. Pharm. (Weinheim) 345 2012 7 21
43. Y. Itoh et al. Small-molecular modulators of cancer-associated epigenetic mechanisms Mol. Biosyst. 9 2013 873 896
44. S. Muller, and P.J. Brown Epigenetic chemical probes Clin. Pharmacol. Ther. 92 2012 689 693
45. K. Helin, and D. Dhanak Chromatin proteins and modifications as drug targets Nature 502 2013 480 488
46. V. Singh et al. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer Curr. Cancer Drug Targets 13 2013 379 399
47. J.M. Foulks et al. Epigenetic drug discovery: targeting DNA methyltransferases J. Biomol. Screen. 17 2012 2 17
48. I. Campesi et al. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function Biol. Sex Differ. 3 2012 4
49. E.E. Nilsson, and M.K. Skinner Environmentally induced epigenetic transgenerational inheritance of disease susceptibility Transl. Res. 2014 10.1016/j.trsl.2014.02.003
50. R. Hewitson et al. Heart failure: the pivotal role of histone deacetylases Int. J. Biochem. Cell Biol. 45 2013 448 453
51. J.C. Black et al. Histone lysine methylation dynamics: establishment, regulation, and biological impact Mol. Cell 48 2012 491 507
52. N.A. Malmquist et al. Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum Proc. Natl. Acad. Sci. U.S.A. 109 2012 16708 16713
53. P. Anand et al. BET bromodomains mediate transcriptional pause release in heart failure Cell 154 2013 569 582
54. M.M. Matzuk et al. Small-molecule inhibition of BRDT for male contraception Cell 150 2012 673 684
55. P. Filippakopoulos et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family Bioorg. Med. Chem. 20 2012 1878 1886
56. D.Y. Liang et al. Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice J. Pain 14 2013 36 47
57. A.J. Sakharkar et al. Histone deacetylases (HDAC)-induced histone modifications in the amygdala: a role in rapid tolerance to the anxiolytic effects of ethanol Alcohol. Clin. Exp. Res. 36 2012 61 71
58. E.J. Nestler Epigenetic mechanisms of drug addiction Neuropharmacology 76 2014 259 268
59. H. Sun et al. Morphine epigenomically regulates behavior through alterations in histone H3 lysine 9 dimethylation in the nucleus accumbens J. Neurosci. 32 2012 17454 17464
60. D.A. Nielsen et al. Epigenetics of drug abuse: predisposition or response Pharmacogenomics 13 2012 1149 1160
61. M. Rebucci, and C. Michiels Molecular aspects of cancer cell resistance to chemotherapy Biochem. Pharmacol. 85 2013 1219 1226
62. K.G. Chen, and B.I. Sikic Molecular pathways: regulation and therapeutic implications of multidrug resistance Clin. Cancer Res. 18 2012 1863 1869
63. M.R. Lackner et al. Mechanisms of acquired resistance to targeted cancer therapies Future Oncol. 8 2012 999 1014
64. S.V. Sharma et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
65. D. Matei et al. Epigenetic resensitization to platinum in ovarian cancer Cancer Res. 72 2012 2197 2205
66. P.G. Richardson et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma Blood 122 2013 2331 2337
67. A. Mai et al. Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans Bioorg. Med. Chem. Lett. 17 2007 1221 1225
68. P. Sharma et al. An epigenetic antimalarial resistance mechanism involving parasite genes linked to nutrient uptake J. Biol. Chem. 288 2013 19429 19440
69. M.L. de Groote et al. Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes Nucleic Acids Res. 40 2012 10596 10613
70. B. Malecova, and K.V. Morris Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs Curr. Opin. Mol. Ther. 12 2010 214 222
71. A.G. Rivenbark et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation Epigenetics 7 2012 350 360
72. S. Stolzenburg et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer Nucleic Acids Res. 40 2012 6725 6740
73. M. Eisenstein Sangamo's lead zinc-finger therapy flops in diabetic neuropathy Nat. Biotechnol. 30 2012 121 123
74. S. Bultmann et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers Nucleic Acids Res. 40 2012 5368 5377
75. E. Dejeux et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response Mol. Cancer 9 2010 68
76. O. Hartmann et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy Clin. Cancer Res. 15 2009 315 323
77. O.A. Stefansson et al. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer Epigenetics 7 2012 1225 1229
78. B. Chen et al. GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response Cancer Lett. 309 2011 37 45
79. M.R. Gilbert et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J. Clin. Oncol. 31 2013 4085 4091
80. N. Syed et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer Cancer Res. 71 2011 3317 3327
81. M.P. Ebert et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer New Engl. J. Med. 366 2012 44 53
82. K. Chiam et al. GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells PLoS One 6 2011 e25634
83. J. Jelinek et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia PLoS One 6 2011 e22110
84. E.Y. Gil et al. Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer Int. J. Oncol. 41 2012 611 620
85. M. Candelaria et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Oncol. 18 2007 1529 1538
86. E. Cervera et al. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia Clin. Lymphoma Myeloma Leuk. 12 2012 207 212
87. M. Candelaria et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome Preliminary results of a phase-II trial. Ann. Hematol. 90 2011 379 387
88. B.F. Chu et al. Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer Cancer Chemother. Pharmacol. 71 2013 115 121
89. P.N. Munster et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Br. J. Cancer 104 2011 1828 1835
90. R. Raqib et al. Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial BMC Infect. Dis. 12 2012 111
91. A. Younes et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study J. Clin. Oncol. 30 2012 2197 2203
92. D.A. Yardley et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor J. Clin. Oncol. 31 2013 2128 2135
93. A. Younes et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial Lancet Oncol. 12 2011 1222 1228